Literature DB >> 21322014

Glia: initiators and progressors of pathology in Parkinson's disease.

Glenda M Halliday1, Claire H Stevens.   

Abstract

BACKGROUND: Glia are traditionally known as support cells for neurons, and their role in neurodegeneration has been largely considered secondary to neuronal dysfunction. We review newer concepts on glial function and assess glial changes in Parkinson's disease (PD) at the time of disease initiation when α-synuclein is accumulating in brain tissue but there is limited neuronal loss, and also as the disease progresses and neuronal loss is evident.
RESULTS: Of the two main types of astrocytes, only protoplasmic astrocytes are involved in PD, where they become nonreactive and accumulate α-synuclein. Experimental evidence has shown that astrocytic α-synuclein deposition initiates the noncell autonomous killing of neurons through microglial signaling. As the disease progresses, more protoplasmic astrocytes are affected by the disease with an increasing microglial response. Although there is still controversy on the role microglia play in neurodegeneration, there is evidence that microglia are activated early in PD and possibly assist with the clearance of extracellular α-synuclein at this time. Microglia transform to phagocytes and target neurons as the disease progresses but appear to become dysfunctional with increasing amounts of ingested debris. Only nonmyelinating oligodendroglial cells are affected in PD, and only late in the disease process.
CONCLUSIONS: Glial cells are responsible for the progression of PD and play an important role in initiating the early tissue response. In particular, early dysfunction and α-synuclein accumulation in astrocytes causes recruitment of phagocytic microglia that attack selected neurons in restricted brain regions causing the clinical symptoms of PD.
Copyright © 2010 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21322014     DOI: 10.1002/mds.23455

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  168 in total

Review 1.  Targeting NOX enzymes in the central nervous system: therapeutic opportunities.

Authors:  Silvia Sorce; Karl-Heinz Krause; Vincent Jaquet
Journal:  Cell Mol Life Sci       Date:  2012-05-30       Impact factor: 9.261

Review 2.  GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.

Authors:  Parker H Johnson; Neal J Weinreb; James C Cloyd; Paul J Tuite; Reena V Kartha
Journal:  Mol Genet Metab       Date:  2019-10-23       Impact factor: 4.797

Review 3.  Astrocytes in neurodegenerative disease.

Authors:  Hemali Phatnani; Tom Maniatis
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-04-15       Impact factor: 10.005

4.  Relationship of neighboring tissue and gliosis to α-synuclein pathology in a fetal transplant for Parkinson's disease.

Authors:  Tae-Beom Ahn; J William Langston; Venkat Raghav Aachi; Dennis W Dickson
Journal:  Am J Neurodegener Dis       Date:  2012-04-18

5.  Exosomes-associated neurodegeneration and progression of Parkinson's disease.

Authors:  Isabella Russo; Luigi Bubacco; Elisa Greggio
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

6.  Preferential Heme Oxygenase-1 Activation in Striatal Astrocytes Antagonizes Dopaminergic Neuron Degeneration in MPTP-Intoxicated Mice.

Authors:  Xiaofeng Xu; Ning Song; Ranran Wang; Hong Jiang; Junxia Xie
Journal:  Mol Neurobiol       Date:  2015-09-18       Impact factor: 5.590

7.  Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson's disease.

Authors:  Marianna Sikorska; Patricia Lanthier; Harvey Miller; Melissa Beyers; Caroline Sodja; Bogdan Zurakowski; Sandhya Gangaraju; Siyaram Pandey; Jagdeep K Sandhu
Journal:  Neurobiol Aging       Date:  2014-04-02       Impact factor: 4.673

Review 8.  α-Synuclein oligomers and clinical implications for Parkinson disease.

Authors:  Lorraine V Kalia; Suneil K Kalia; Pamela J McLean; Andres M Lozano; Anthony E Lang
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

9.  Fingolimod Suppresses the Proinflammatory Status of Interferon-γ-Activated Cultured Rat Astrocytes.

Authors:  Saša Trkov Bobnar; Matjaž Stenovec; Katarina Miš; Sergej Pirkmajer; Robert Zorec
Journal:  Mol Neurobiol       Date:  2019-01-30       Impact factor: 5.590

10.  Knocking out DJ-1 attenuates astrocytes neuroprotection against 6-hydroxydopamine toxicity.

Authors:  Nirit Lev; Yael Barhum; Tali Ben-Zur; Eldad Melamed; Israel Steiner; Daniel Offen
Journal:  J Mol Neurosci       Date:  2013-03-28       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.